Education
About Us
Working with TipRanks
Follow Us
VolitionRX (VNRX)
:VNRX
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.06Last Year’s EPS
-0.1Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 31, 2025
|% Change Since: -15.79%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
VolitionRx showed significant progress in 2024 with strong revenue growth, successful cost reduction, and promising clinical advancements in both oncology and sepsis. However, challenges remain in achieving predictable revenue streams and cash flow management. The company's focus on securing multiple licensing deals in 2025 is critical to future success.Company Guidance
During the VolitionRx Limited Fourth Quarter and Full Fiscal Year 2024 Earnings Conference Call, key guidance was provided for 2025. The company aims to achieve cash neutrality, meaning that income, including licensing receipts, will match expenditures on a cash basis. In 2024, VolitionRx reported $1.2 million in revenue, a 59% increase from 2023, with Nu.Q Vet Cancer Test sales growing by 75% to $0.8 million, and Nu.Q Discover revenue rising by 40% to $0.4 million. Approximately 120,000 Nu.Q Vet cancer tests were sold, more than doubling the prior year's sales. Operating expenses were reduced by 23% year-on-year, contributing to a 17% reduction in net cash used in operating activities when excluding previous milestone payments. The company is focused on signing multiple human licensing deals in 2025, replicating its success in the veterinary space, with plans to automate centralized labs to accelerate growth and expand the use of its Nu.Q platform in clinical settings.Nu.Q Vet Cancer Test Expansion
The Nu.Q Vet Cancer Test expanded access to over 20 countries and sold approximately 120,000 tests in 2024, doubling the previous year and resulting in a 75% increase in vet revenue compared to 2023.
Significant Revenue Growth
VolitionRx recorded $1.2 million in revenue for 2024, a 59% increase from 2023. Nu.Q Vet Cancer Test revenue grew by 75%, and Nu.Q Discover revenue grew by 40%.
Cost Reduction Success
Operating expenses were reduced by 23% year-over-year, with a 31% reduction in the second half of 2024 compared to the previous year.
Nu.Q Cancer Clinical Progress
The Nu.Q Cancer platform demonstrated its ability to differentiate between malignant and benign pulmonary nodules in an 800-patient study, with further validation studies underway.
Nu.Q NETs Sepsis Marker Success
Nu.Q NETs test showed promising results across multiple studies as a surrogate marker for neutrophil extracellular traps (NETs) in sepsis, generating interest from key opinion leaders and licensing partners.
Nu.Q Discover Pharmaceutical Partnerships
VolitionRx entered into its first human clinical study partnership with a leading pharmaceutical company, expected to generate significant revenue and validate the Nu.Q Discover program.
---
VNRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VNRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 31, 2025 | $0.57 | $0.52 | -8.77% |
| Nov 14, 2024 | $0.72 | $0.68 | -5.56% |
| Aug 14, 2024 | $0.55 | $0.57 | +3.64% |
| May 13, 2024 | $0.88 | $0.75 | -14.77% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does VolitionRX (VNRX) report earnings?
VolitionRX (VNRX) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is VolitionRX (VNRX) earnings time?
VolitionRX (VNRX) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VNRX EPS forecast?
VNRX EPS forecast for the fiscal quarter 2025 (Q1) is -0.06.
---